Objective To investigate the association between 25-hydroxyvitamin D3 [25(OH)D3] and chronic kidney disease-associated pruritus (CKD-aP) in patients on maintenance hemodialysis (MHD) or peritoneal dialysis (PD), and the predictive value of 25(OH)D3 level for CKD-aP in dialysis patients. Methods In this single-center, cross-sectional study, patients with MHD, or PD treatment from 1 January 2022 to 31 December 2022 in the Zhongda Hospital, affiliated with Southeast University were selected as subjects. Based on the absence of CKD-aP, the patients were divided into the non-pruritus and pruritus groups, then compare the clinical data and 25(OH)D3 level between the two groups. The pruritus group further divided into mild and moderate-to-severe pruritus based on the pruritus score. Then we compared the 25(OH)D3 levels in the general population, MHD, and PD patients in different itching severity groups. The ROC curve was used to analyze the clinical value of 25(OH)D3 in predicting the occurrence of CKD-aP in dialysis patients. Results A total of 331 dialysis patients were included, including 238 patients with MHD and 93 patients with PD. The prevalence of CKD-aP was 56.5%, 58.4% and 51.6%, respectively. The 25(OH)D3 in the pruritus group of MHD and PD patients was lower than that in the non-pruritus group (MHD: 13.490 (10.140, 17.980) vs. 18.900 (10.910, 24.630), Z=-3.538, P<0.001; PD: 7.215 (4.843, 11.875) vs. 12.090 (6.630, 15.240), Z=-3.075, P=0.002). Further analysis showed that There were statistically differences in 25(OH)D3 among no pruritus group, mild pruritus group, and moderate to severe pruritus group (total population: H=28.823 P<0.001; MHD: H=25.137 P<0.001; PD: H=12.228 P=0.002). 25(OH)D3 decreased with the increase of pruritus in the total population and MHD patients (P<0.05). The 25(OH)D3 in the non-pruritus group was higher than that in the mild pruritus group (P=0.015) and the moderate-to-severe pruritus group (P=0.003), and there was no significant difference in 25(OH)D3 between the mild pruritus group and the moderate-to-severe pruritus group (P=0.081). The results of multivariate logistic regression analysis showed that white blood cell count (OR=1.257, 95% CI: 1.033～1.529, P=0.022), serum phosphorus (OR=2.277, 95% CI: 1.215～4.268, P=0.010), parathyroid hormone (OR=1.002, 95% CI: 1.000～1.003, P=0.018), β2-microglobulin (OR=1.039, 95% CI: 1.007～1.073, P=0.017) were risk factors for CKD-aP in MHD patients, and serum phosphorus (OR=4.613, 95% CI: 1.354～15.719,P=0.015) and hypersensitive C-reactive protein (OR=1.192, 95% CI: 1.019～1.395, P=0.028) were risk factors for CKD-aP in PD patients. 25(OH)D3 was a protective factor for CKD-aP in patients with MHD and PD (MHD: OR=0.937, 95% CI: 0.901～0.975, P=0.001. PD: OR=0.909, 95% CI: 0.830～0.995, P=0.038). The ROC curve showed that the predicted AUC was 0.635 when the 25(OH)D3<18.835 ng/ml in MHD patients and 0.685 when the 25(OH)D3<10.545 ng/ml in PD patients. Conclusions Lower 25(OH)D3 may play an important role in CKD-aP in dialysis patients. Moreover, 25(OH)D3 level has certain clinical value in predicting the occurrence of CKD-aP in dialysis patients.
JI Bo-Fan
,
CHEN Jing-Jing
,
MA Xue-Jie
,
ZHANG Xiao-Liang
,
TANG Ri-Ning
. Correlation analysis of 25-hydroxyvitamin D3 with chronic kidney disease-associated pruritus in dialysis patients[J]. Chinese Journal of Blood Purification, 2024
, 23(11)
: 807
-812
.
DOI: 10.3969/j.issn.1671-4091.2024.11.002
[1]. Yang, M., et al., Complications of progression of CKD. Adv Chronic Kidney Dis, 2011. 18(6): p. 400-5.
[2]. Kim, D. and C. Pollock, Epidemiology and burden of chronic kidney disease-associated pruritus. Clin Kidney J, 2021. 14(Suppl 3): p. i1-i7.
[3]. Molina, P., et al., Etiopathogenesis of chronic kidney disease-associated pruritus: putting the pieces of the puzzle together. Nefrologia (Engl Ed), 2023. 43(1): p. 48-62.
[4]. Bikle, D.D., Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol, 2014. 21(3): p. 319-29.
[5]. Jung, K.E., et al., Effect of topical vitamin D on chronic kidney disease-associated pruritus: An open-label pilot study. J Dermatol, 2015. 42(8): p. 800-3.
[6]. Wu, H.Y., et al., A Comparison of Uremic Pruritus in Patients Receiving Peritoneal Dialysis and Hemodialysis. Medicine (Baltimore), 2016. 95(9): p. e2935.
[7]. Dilek Gokustun, A.Z.B.S., 25-Hydroxy Vitamin D Deficiency May Be the Secret Actor in the Pathogenesis of Uremic Pruritus in Hemodialysis Patients. Journal of Clinical Nephrology and Research, 2016.
[8]. 孙达等, 慢性肾脏病患者25-羟维生素D3水平的改变及其影响因素分析. 临床肾脏病杂志, 2016. 16(05): 第265-270页.
[9]. Verduzco, H.A. and S. Shirazian, CKD-Associated Pruritus: New Insights Into Diagnosis, Pathogenesis, and Management. Kidney Int Rep, 2020. 5(9): p. 1387-1402.
[10]. Nochaiwong, S., et al., Clinical interpretation of the Uremic Pruritus in Dialysis Patients (UP-Dial) scale: a novel instrument for the assessment of uremic pruritus. J Eur Acad Dermatol Venereol, 2018. 32(7): p. 1188-1194.
[11]. Abdallah, A.M., S.M. Elsheikh and R.A. ElBarbary, Prevalence and determinants of severity of uremic pruritus in hemodialysis patients: a multicentric study. J Investig Med, 2023. 71(1): p. 42-46.
[12]. Fallahzadeh, M.K., et al., Interleukin-2 serum levels are elevated in patients with uremic pruritus: a novel finding with practical implications. Nephrol Dial Transplant, 2011. 26(10): p. 3338-44.
[13]. Keshari, S., et al., IL-6/p-BTK/p-ERK signaling mediates calcium phosphate-induced pruritus. FASEB J, 2019. 33(11): p. 12036-12046.
[14]. Ruzicka, T., et al., Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. N Engl J Med, 2017. 376(9): p. 826-835.
[15]. Silverberg, J.I., et al., Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol, 2020. 145(1): p. 173-182.
[16]. Molina, P., et al., The effect of high-volume online haemodiafiltration on nutritional status and body composition: the ProtEin Stores prEservaTion (PESET) study. Nephrol Dial Transplant, 2018. 33(7): p. 1223-1235.
[17]. Obi, Y., et al., Vitamin D Receptor Activator Use and Cause-specific Death among dialysis Patients: a Nationwide Cohort Study using Coarsened Exact Matching. Sci Rep, 2017. 7: p. 41170.
[18]. Momose, A., et al., Calcium ions are abnormally distributed in the skin of haemodialysis patients with uraemic pruritus. Nephrol Dial Transplant, 2004. 19(8): p. 2061-6.
[19]. Sadeghi, K., et al., Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol, 2006. 36(2): p. 361-70.
[20]. Penna, G. and L. Adorini, 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol, 2000. 164(5): p. 2405-11.
[21]. Lang, C.L., et al., Vitamin D and the Immune System from the Nephrologist's Viewpoint. ISRN Endocrinol, 2014. 2014: p. 105456.
[22]. Brozyna, A.A., et al., Vitamin D Signaling in Psoriasis: Pathogenesis and Therapy. Int J Mol Sci, 2022. 23(15).
[23]. Goetz, D.W., Vitamin D treatment of idiopathic itch, rash, and urticaria/angioedema. Allergy Asthma Proc, 2010. 31(2): p. 158-60.
[24]. Malekmakan, L., et al., Role of vitamin D in oxidative stress modulation in end-stage renal disease patients: A double-blind randomized clinical trial. Hemodial Int, 2020. 24(3): p. 367-373.
[25]. Kimmel, M., et al., The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant, 2006. 21(3): p. 749-55.
[26]. 王颖与毕慧欣, 维持性血液透析患者皮肤瘙痒相关机制的研究进展. 中国血液净化, 2021. 20(01): 第43-46页.
[27]. Kemeny, L.V., et al., Vitamin D deficiency exacerbates UV/endorphin and opioid addiction. Sci Adv, 2021. 7(24).
[28]. Wimalawansa, S.J., Controlling Chronic Diseases and Acute Infections with Vitamin D Sufficiency. Nutrients, 2023. 15(16).
[29]. Andoh, T., et al., beta2-Microglobulin elicits itch-related responses in mice through the direct activation of primary afferent neurons expressing transient receptor potential vanilloid 1. Eur J Pharmacol, 2017. 810: p. 134-140
